Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
about
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?Regulatory considerations on endpoints in ovarian cancer drug development.A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaDNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach.Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.Real-world evidence in the treatment of ovarian cancer.Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety.National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery.Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Model for Prediction of Optimal Debulking of Epithelial Ovarian CancerOvarian microcystic stromal tumor: Radiologic-pathologic correlation.Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States
P2860
Q33563963-1967CC6F-A608-4E07-A922-8704960206C5Q38631105-C3D359A4-1C0D-46D6-AB54-60CA6A96DD52Q38680412-80A60515-F610-4876-BB13-FC62BF790309Q38764674-21770B5B-2AFA-4A8D-AE83-48C9E923AEF4Q38769834-BDDD5486-8B69-47EE-B26B-E6D76DD1E763Q38941559-DD6293BD-684B-4F14-81DE-43EB21192948Q39302770-E3AE687C-9110-430C-B4A7-AF87588B4F67Q40331453-6EEF160A-85CF-4A8A-B2C5-2CB66DBA4AECQ40443819-3A07563E-702E-4EFF-AABE-9B423A24D58BQ41557623-5F66B610-1461-4DBC-A529-2167BB89FE04Q46540302-216FC342-879C-4D96-BE10-4FB858880B7FQ47107718-8E7FDFD3-7B1D-4C3F-B813-688567AF5ED5Q47148453-0D4457D4-F937-4D69-BE9E-1127D3E5C2AAQ47151877-CDA1A7DF-843C-4986-A0A2-D7D6146C93A9Q47257079-2240B9FD-A6D7-4FEE-B623-93F05AF8EE76Q47324006-DCFEF63A-78E5-4361-A61D-BA80C514DA90Q47603079-939D1EC3-E6BA-4D15-81E4-B48E6D6E18FAQ47913533-170445BD-4DB6-43B5-A48F-F2328560678BQ48008944-3B2E5394-7572-45B7-954D-E8387380D48DQ49337608-480D0465-973E-4647-8CC8-EE190C4CEA2DQ49894154-5C0A2DDE-AD98-4C89-A700-BED66CD2C15FQ55041688-C0BAA801-BCB9-4A99-B3C4-9E010CB18833Q55638402-95586625-B8EC-4FDE-9DEA-BA6469314CA1Q55691405-355A2CAF-5DBF-4710-B176-AB762712C369Q57171698-2D02FC9F-7099-4499-9493-23F3E6DCA6ED
P2860
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@en
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@nl
type
label
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@en
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@nl
prefLabel
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@en
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@nl
P2093
P2860
P356
P1476
Neoadjuvant Chemotherapy for N ...... y Clinical Practice Guideline.
@en
P2093
Alexander B Olawaiye
Alexi A Wright
Deborah K Armstrong
Dee Sparacio
Don S Dizon
Jessica Oldham
Joseph J Kash
Kari Bohlke
Kathleen N Moore
Larissa A Meyer
P2860
P304
P356
10.1200/JCO.2016.68.6907
P407
P577
2016-08-08T00:00:00Z